{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Germ+Cell+and+Embryonal&page=8",
    "query": {
      "condition": "Neoplasms, Germ Cell and Embryonal",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 5147,
    "total_pages": 515,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Germ+Cell+and+Embryonal&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Germ+Cell+and+Embryonal&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T12:07:56.701Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03232424",
      "title": "NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma, Adult"
      ],
      "interventions": [
        {
          "name": "NovoTTF-200A",
          "type": "DEVICE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "3D conformal or intensity modulated radiation therapy (IMRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-07-26",
      "completion_date": "2022-12-07",
      "has_results": false,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-11-15T12:07:56.701Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03232424"
    },
    {
      "nct_id": "NCT00929903",
      "title": "Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Central Nervous System Choriocarcinoma",
        "Childhood Central Nervous System Embryonal Tumor",
        "Childhood Central Nervous System Germ Cell Tumor",
        "Childhood Central Nervous System Germinoma",
        "Childhood Central Nervous System Mixed Germ Cell Tumor",
        "Childhood Central Nervous System Teratoma",
        "Childhood Central Nervous System Yolk Sac Tumor",
        "Metastatic Childhood Soft Tissue Sarcoma",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Central Nervous System Embryonal Tumor",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Childhood Visual Pathway Glioma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "pazopanib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 55,
      "start_date": "2009-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-30",
      "last_synced_at": "2026-11-15T12:07:56.701Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Indianapolis, Indiana + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00929903"
    },
    {
      "nct_id": "NCT06541262",
      "title": "Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Ewing Sarcoma",
        "Osteosarcoma",
        "Rhabdomyosarcoma",
        "Liposarcoma"
      ],
      "interventions": [
        {
          "name": "Silmitasertib",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 104,
      "start_date": "2024-10-30",
      "completion_date": "2035-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-15T12:07:56.701Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06541262"
    },
    {
      "nct_id": "NCT05688280",
      "title": "Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Solid Tumor",
        "Colon Cancer",
        "Nonsmall Cell Lung Cancer",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "1.0% IP-001 for Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunophotonics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2022-11-29",
      "completion_date": "2025-02",
      "has_results": false,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-11-15T12:07:56.701Z",
      "location_count": 3,
      "location_summary": "Coral Gables, Florida • Louisville, Kentucky • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05688280"
    },
    {
      "nct_id": "NCT00085579",
      "title": "Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2004-03",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2012-12-12",
      "last_synced_at": "2026-11-15T12:07:56.701Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085579"
    },
    {
      "nct_id": "NCT02451488",
      "title": "Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2015-05",
      "completion_date": "2016-11-04",
      "has_results": true,
      "last_update_posted_date": "2020-02-10",
      "last_synced_at": "2026-11-15T12:07:56.701Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02451488"
    },
    {
      "nct_id": "NCT07751042",
      "title": "Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "STX-003",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KEYTRUDA®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Strand Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2026-06-30",
      "completion_date": "2030-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-15T12:07:56.701Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07751042"
    },
    {
      "nct_id": "NCT01024387",
      "title": "AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumor",
        "Carcinoid Tumor",
        "Pancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "AMG 479",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2010-03",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2018-03-08",
      "last_synced_at": "2026-11-15T12:07:56.701Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Boston, Massachusetts",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01024387"
    },
    {
      "nct_id": "NCT00295906",
      "title": "Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma (Skin)",
        "Non-melanomatous Skin Cancer"
      ],
      "interventions": [
        {
          "name": "educational intervention",
          "type": "OTHER"
        },
        {
          "name": "internet-based intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Rhode Island Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4550,
      "start_date": "2004-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-11-15T12:07:56.701Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Wichita, Kansas • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00295906"
    },
    {
      "nct_id": "NCT02499952",
      "title": "Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Germ Cell Neoplasms",
        "Testicular Neoplasms",
        "Non Seminomatous Germ Cell Tumors",
        "Mediastinal Neoplasms",
        "Genital Neoplasms, Male",
        "Genital Neoplasms, Female",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nasser Hanna, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2016-01",
      "completion_date": "2017-01-13",
      "has_results": true,
      "last_update_posted_date": "2022-07-11",
      "last_synced_at": "2026-11-15T12:07:56.701Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02499952"
    }
  ]
}